Bevacizumab Plus Chemotherapy in Patients With Early Stage HER2-Negative Breast Cancer

from Cancer Network Podcasts · host Cancer Network

Dr. Gunter von Minckwitz discusses the recent paper he authored that showed that bevacizumab in addition to neoadjuvant chemotherapy significantly increased the rate of pathological complete response in patients with early stage HER2-negative breast cancer.

Episode metadata supplied by the publisher feed · Published Feb 13, 2012

Embed this episode

Attribution link and audio player

NOW PLAYING

Bevacizumab Plus Chemotherapy in Patients With Early Stage HER2-Negative Breast Cancer

0:00 10:45

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Cancer Network Podcasts?

This episode is 10 minutes long.

When was this Cancer Network Podcasts episode published?

This episode was published on February 13, 2012.

Can I download this Cancer Network Podcasts episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!